Furthermore, Metformin was found to reduce breast cancer cell viability, upregulated miR-26a, and reduced expression of miR-26a targets PTEN and EHZ2 in several breast cancer cell lines (Cabello et al., 2016). Here, PTEN is linked to breast cancer.